<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Coronavirus disease 2019 (COVID-19) was reported as a global pandemic in March 2020 after invading many countries and leaving behind tens of thousands of infected patients in a brief time span. Approval of a few vaccines has been obtained and their efficacy of varying degrees established. Still, there is no effective pharmaceutical agent for the treatment of COVID-19 though several drugs are undergoing clinical trials. Recent studies have shown that dexamethasone, a corticosteroid, can reduce the rate of COVID-19-related mortality in the intensive care unit by 35 % for patients who are on mechanical ventilation. Although variable efficacy of other combination therapies has been reported for treating COVID-19 associated with acute respiratory distress syndrome (ARDS), dexamethasone is an extensively used drug in many treatment regimens against COVID-19. The current review aims to explore the role of dexamethasone as an efficient combination treatment for COVID-19.</p>
</abstract>

Coronavirus disease 2019 (COVID-19) was reported as a global pandemic in March 2020 after invading many countries and leaving behind tens of thousands of infected patients in a brief time span. Approval of a few vaccines has been obtained and their efficacy of varying degrees established. Still, there is no effective pharmaceutical agent for the treatment of COVID-19 though several drugs are undergoing clinical trials. Recent studies have shown that dexamethasone, a corticosteroid, can reduce the rate of COVID-19-related mortality in the intensive care unit by 35 % for patients who are on mechanical ventilation. Although variable efficacy of other combination therapies has been reported for treating COVID-19 associated with acute respiratory distress syndrome (ARDS), dexamethasone is an extensively used drug in many treatment regimens against COVID-19. The current review aims to explore the role of dexamethasone as an efficient combination treatment for COVID-19.

The effectiveness of dexamethasone as a combination therapy for COVID-19

Pharmaceutics and Pharmaceutical Technology Department College of Pharmacy

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"The effectiveness of dexamethasone as a combination therapy for COVID-19"}

Coronavirus disease 2019 (COVID-19) was reported as a global pandemic in March 2020 after invading many countries and leaving behind tens of thousands of...

The effectiveness of dexamethasone as a combination therapy for COVID-19

Data publikacji: 13 kwi 2022

Zakres stron: 345 - 358

Przyjęty: 28 sty 2022

DOI: https://doi.org/10.2478/acph-2022-0030

Słowa kluczowe
dexamethasone, glucocorticosteroids, acute respiratory distress syndrome, Coronavirus disease 2019, combination therapy, SARS-CoV-2, immunosuppressive

© 2022 Nader Namazi, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The effectiveness of dexamethasone as a combination therapy for COVID-19

Data publikacji: 13 kwi 2022

Zakres stron: 345 - 358

Przyjęty: 28 sty 2022

DOI: https://doi.org/10.2478/acph-2022-0030

Słowa kluczowedexamethasone, glucocorticosteroids, acute respiratory distress syndrome, Coronavirus disease 2019, combination therapy, SARS-CoV-2, immunosuppressive

© 2022 Nader Namazi, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Słowa kluczowe
dexamethasone, glucocorticosteroids, acute respiratory distress syndrome, Coronavirus disease 2019, combination therapy, SARS-CoV-2, immunosuppressive